Table 1. Clinical characteristics of TCGA-BRCA level 3 cohort.
| Characteristics | Numbers of cases (%) |
|---|---|
| CCBL2 | |
| High | 746(67.57) |
| Low | 358(32.43) |
| Age | |
| <60 | 589(53.45) |
| > = 60 | 513(46.55) |
| Gender | |
| Female | 1090(98.73) |
| Male | 12(1.09) |
| NA | 2(0.18) |
| Histological type | |
| Infiltrating Ductal Carcinoma | 790(71.56) |
| Infiltrating Lobular Carcinoma | 204(18.48) |
| Other | 107(9.69) |
| NA | 3(0.27) |
| Molecular subtype | |
| Basal | 142(12.86) |
| HER-2 | 67(6.07) |
| Lum A | 422(38.22) |
| Lum B | 194(17.57) |
| Normal | 24(2.17) |
| NA | 255(23.1) |
| ER | |
| Indeterminate | 2(0.18) |
| Negative | 239(21.65) |
| Positive | 813(73.64) |
| NA | 50(4.53) |
| PR | |
| Indeterminate | 4(0.36) |
| Negative | 345(31.25) |
| Positive | 704(63.77) |
| NA | 51(4.62) |
| HER-2 | |
| Equivocal | 180(16.3) |
| Indeterminate | 12(1.09) |
| Negative | 565(51.18) |
| Positive | 164(14.86) |
| NA | 183(16.58) |
| T classification | |
| T1 | 281(25.45) |
| T2 | 640(57.97) |
| T3 | 138(12.5) |
| T4 | 40(3.62) |
| TX | 3(0.27) |
| NA | 2(0.18) |
| N classification | |
| N0 | 516(46.74) |
| N1 | 367(33.24) |
| N2 | 120(10.87) |
| N3 | 79(7.16) |
| NX | 20(1.81) |
| NA | 2(0.18) |
| M classification | |
| M0 | 917(83.06) |
| M1 | 22(1.99) |
| MX | 163(14.76) |
| NA | 2(0.18) |
| Stage | |
| I | 182(16.49) |
| II | 626(56.7) |
| III | 252(22.83) |
| IV | 20(1.81) |
| X | 14(1.27) |
| NA | 10(0.91) |
| Lymph node status | |
| No | 28(2.54) |
| Yes | 697(63.13) |
| NA | 379(34.33) |
| Vital status | |
| Deceased | 155(14.04) |
| Living | 947(85.78) |
| NA | 2(0.18) |
| Sample type | |
| Metastatic | 7(0.63) |
| Primary tumor | 1097(99.37) |
| Menopause status | |
| Inde | 34(3.08) |
| Peri | 40(3.62) |
| Post | 706(63.95) |
| Pre | 231(20.92) |
| NA | 93(8.42) |
| Margin status | |
| Close | 31(2.81) |
| Negative | 922(83.51) |
| Positive | 79(7.16) |
| NA | 72(6.52) |
| Radiation therapy | |
| NO | 445(40.31) |
| YES | 557(50.45) |
| NA | 102(9.24) |
| Neoadjuvant treatment | |
| No | 1088(98.55) |
| Yes | 13(1.18) |
| NA | 3(0.27) |
| Targeted molecular therapy | |
| NO | 46(4.17) |
| YES | 533(48.28) |
| NA | 525(47.55) |
| Os | |
| Alive | 933(85.83) |
| Dead | 154(14.17) |
| Rfs | |
| Relapse-free | 816(89.47) |
| Relapse | 96(10.53) |
Abbreviation: ER: estrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor-2; T: tumor; M: metastasis; N: node; OS: overall survival; RFS: relapse-free survival; NA: not available.